Humans and microbes have been, and always will be in constant evolutionary competition with each other. As humans develop ways of inhibiting bacterial growth, such as the use of antibiotics to treat bacterial infections, bacteria are constantly evolving new ways to evade bacterial targets. Over the last several decades, antibiotics have become overused and often inappropriately prescribed leading to the increase in antibiotic resistance cases seen now in thousands of bacterial strains. One of the ways to combat the increasing antibiotic resistance crisis is by developing new ways to counteract evolving bacterial strains, such as the use of amino acid based surfactants to eliminate bacterial populations. Leucine and phenylalanine surfactants previously produced at Carthage have already proven effective in inhibiting bacterial growth in Escherichia coli (gram negative) and Staphylococcus aureus (gram positive). The leucine surfactant is currently being tested on additional bacterial species, Acinetobacter baylyi (gram negative) and Enterococcus faecalis (gram positive) to determine the minimum inhibitory concentration (MIC), the minimum concentration of surfactant required to inhibit bacterial growth. All tests are conducted using standard serial dilution protocol, are conducted in triplicate to ensure MIC results accuracy, and all bacterial strains used are non-pathogenic representatives of antibiotic-resistant bacteria. Analysis of the surfactant’s activity will help determine future potential use as an antimicrobial agent.